Chris Smith is the CEO of NeoGenomics, Inc. He has been with the company since August 15, 2022, bringing a wealth of experience from his previous role as CEO of Ortho Clinical Diagnostics. Smith also held significant positions at Cochlear...
Chris Smith is the CEO of NeoGenomics, Inc. He has been with the company since August 15, 2022, bringing a wealth of experience from his previous role as CEO of Ortho Clinical Diagnostics. Smith also held significant positions at Cochlear Limited, where he served as CEO and President of Cochlear Americas. His educational background includes a Bachelor of Science degree from Texas A&M University. Under his leadership, NeoGenomics has focused on developing strong business strategies and improving fiscal performance. In 2022, his total compensation was approximately $18.5 million, highlighting the company's commitment to aligning executive pay with performance. Since joining NeoGenomics, Smith has emphasized a customer-first mindset and has implemented a robust succession planning strategy. Interestingly, he received a substantial relocation benefit and an inducement equity award worth around $11.85 million, indicating the company's investment in his leadership. Smith's track record shows a commitment to driving strategic growth and operational improvements.